10-67797189-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_021800.3(DNAJC12):c.524G>A(p.Trp175*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000973 in 1,613,658 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.00022 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000084 ( 0 hom. )
Consequence
DNAJC12
NM_021800.3 stop_gained
NM_021800.3 stop_gained
Scores
3
3
1
Clinical Significance
Conservation
PhyloP100: 2.86
Genes affected
DNAJC12 (HGNC:28908): (DnaJ heat shock protein family (Hsp40) member C12) This gene encodes a member of a subclass of the HSP40/DnaJ protein family. Members of this family of proteins are associated with complex assembly, protein folding, and export. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.122 CDS is truncated, and there are 3 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 10-67797189-C-T is Pathogenic according to our data. Variant chr10-67797189-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 870655.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr10-67797189-C-T is described in Lovd as [Pathogenic]. Variant chr10-67797189-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNAJC12 | NM_021800.3 | c.524G>A | p.Trp175* | stop_gained | 5/5 | ENST00000225171.7 | NP_068572.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DNAJC12 | ENST00000225171.7 | c.524G>A | p.Trp175* | stop_gained | 5/5 | 1 | NM_021800.3 | ENSP00000225171.2 | ||
DNAJC12 | ENST00000483798.6 | c.614G>A | p.Trp205* | stop_gained | 6/6 | 3 | ENSP00000474215.1 |
Frequencies
GnomAD3 genomes AF: 0.000223 AC: 34AN: 152150Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
34
AN:
152150
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000172 AC: 43AN: 250564Hom.: 0 AF XY: 0.000192 AC XY: 26AN XY: 135592
GnomAD3 exomes
AF:
AC:
43
AN:
250564
Hom.:
AF XY:
AC XY:
26
AN XY:
135592
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000842 AC: 123AN: 1461390Hom.: 0 Cov.: 30 AF XY: 0.0000784 AC XY: 57AN XY: 726956
GnomAD4 exome
AF:
AC:
123
AN:
1461390
Hom.:
Cov.:
30
AF XY:
AC XY:
57
AN XY:
726956
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000223 AC: 34AN: 152268Hom.: 0 Cov.: 33 AF XY: 0.000269 AC XY: 20AN XY: 74464
GnomAD4 genome
AF:
AC:
34
AN:
152268
Hom.:
Cov.:
33
AF XY:
AC XY:
20
AN XY:
74464
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
16
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Hyperphenylalaninemia due to DNAJC12 deficiency Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Apr 14, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | New York Genome Center | Jul 22, 2021 | - - |
Pathogenic, no assertion criteria provided | research | Centro de Biología Molecular Severo Ochoa, Universidad Autónoma de Madrid | Feb 12, 2020 | - - |
DNAJC12-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 13, 2023 | The DNAJC12 c.524G>A variant is predicted to result in premature protein termination (p.Trp175*). This variant has been reported in the homozygous and compound heterozygous state in multiple individuals with hyperphenylalaninaemia (Navarrete et al 2019. PubMed ID: 30626930; Gallego D et al 2020. PubMed ID: 32333439). This variant is reported in 0.093% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/10-69556947-C-T). Nonsense variants in DNAJC12 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 30, 2021 | The c.524G>A (p.W175*) alteration, located in exon 5 (coding exon 5) of the DNAJC12 gene, consists of a G to A substitution at nucleotide position 524. This changes the amino acid from a tryptophan (W) to a stop codon at amino acid position 175. This alteration occurs at the 3' terminus of the DNAJC12 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 12.2% (24/198 amino acids) of the protein. However, premature stop codons are typically deleterious in nature and a significant portion of the protein is affected (Ambry internal data). This alteration has been detected in the homozygous and compound heterozygous states in multiple individuals with hyperphenylalaninemia (HPA) (Gallego, 2020). Functional studies on fibroblasts showed reduced amounts of PAH and PAH activity affecting the PAH folding process. Steady-state tyrosine hydroxylase levels were also reduced while tryptophan hydroxylase 2 levels were not affected (Gallego, 2020). Based on the available evidence, this alteration is classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 02, 2024 | This sequence change creates a premature translational stop signal (p.Trp175*) in the DNAJC12 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 24 amino acid(s) of the DNAJC12 protein. This variant is present in population databases (rs370032864, gnomAD 0.1%). This premature translational stop signal has been observed in individuals with hyperphenylalaninemia (PMID: 30626930, 32333439). ClinVar contains an entry for this variant (Variation ID: 870655). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects DNAJC12 function (PMID: 32333439). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at